177Lu-DOTA-SNA040

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug Name177Lu-DOTA-SNA040
Drug Alias Name177Lu-DOTA-SNA040
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Heterocyclic drugs
Mechanisms of ActionClaudin 18 protein modulatorsPositron-emission tomography enhancers
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSmartnuclide Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesSmartnuclide Biopharma
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A